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Ever since the report of Gentles (1) that
griseofulvin cured infections due to 3liero.sporom
canis and Trichophyton mentagrophytes in guinea
pigs, this drug has aroused intense interest as a
therapeutic agent for superficial mycoses. While
Gentles originally administered griseofulvin at a
dosage of 60 mg/kg/day, he subsequently found
(2) 15 mg/kg/day to be an effective dose in
guinea pigs. Martin (3) successfully treated T.
mentagrophytes infections in guinea pigs with
griseofulvin at 25 mg/kg/day and to some extent
with lower doses. Lauder and O'Sullivan (4)
found 60 mg/kg/day to be effective in curing
existing infections and in preventing experimental
infections in cattle with T. verrucosum.
Clinical experience in man by others (2, 5, 6)
and by our group has amply demonstrated the
efficacy of griseofulvin in many forms of mycotic
infection. Blank and Roth (7) have demonstrated
the high degree of sensitiveness of many dermato-
phytes to griseofulvin but noted that the deep
fungi and Candida albicans are insensitive. We
have been able to confirm these findings in as
yet unpublished studies.
In man, the most commonly used dosage for
the treatment of superficial fungous infections
hitherto has been 1000 mg per day. Based on an
average weight of 70 kg, this amounts to 14.3
mg/kg/day, a figure which is very close to the 15
mg/kg/day dosage used by several investigators
in laboratory animals.
In our own studies, we attempted to investigate
a number of questions which, thus far, have not
been elucidated: What is the minimal effective
dose of griseofulvin per kg/day in infected ani-
mals? Can a quicker healing of the lesions be
anticipated with larger than the minimal effective
doses? How does the speed of healing compare
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from the clinical, histologic and microbiologic
viewpoints? What is the minimal preventive
dose? Is there a lasting prophylactic action of
griseofulvin after the drug has been discontinued?
EXPERIMENTAL
In order to ascertain the minimal effective dose
and the relative speed of healing of fungous infec-
tions on various doses of orally administered
griseofulvin, we treated 38 guinea pigs which had
been experimentally infected with M. canis for this
purpose. Wood's light positive hairs from another
infected guinea pig had been applied to a slightly
scarified area on the flank. Ten to fourteen days
later, when the fungous lesions were well de-
veloped and fluoresced under Wood's light, treat-
ment was started by force-feeding of water sus-
pensions of griseofulvin*. Groups of animals
received 60, 30, 15, 10, 6 or 3 mg per kg of body
weight daily, 5 days a week for 4—5 weeks.
Guinea pigs were also infected but left un-
treated to serve as a control for comparison with
griseofulvin-fed animals.
Animals were observed clinically at intervals of
1 to 3 days. Cultures and Wood's light examina-
tions were made approximately weekly.
RESULTS
In six animals, fed 60 mg/kg/day, slight clinical
improvement was noted as early as the third day
after the start of therapy; there was less erythema
than in the untreated control animals, and bloody
crusts had not formed in the treated animals.
After seven days (i.e. a total of 5 feedings) the
lesions were definitely in the process of cure, the
inoculated sites showing only slight scaling with
no erythema. Control animals at this time had
bloody crusted lesions with surrounding cry-
thema. After 9 days, hair had started to regrow
in all six animals and after 14 days they appeared
clinically cured. However, it should be noted that,
even after 14 days, the previously affected sites
continued to fluoresce and were still culturally
positive for M. canis. Figures 1—5 show a typical
*Griseofulvin was supplied by Dr. Gavin
Hildick-Smith of Johnson & Johnson, New Bruns-
wick, New Jersey.
FIG. 2. GP 149. One week after start of feedings.
(60 mg/kg). Infected 20 days previously.
therapeutic response in a guinea pig receiving
60 mg/kg, as well as an untreated control animal.
In 5 animals, fed 30 mg/kg/day, the first signs
of clinical improvement, noted on the fourth day
after starting treatment, were decreased ery-
thema and crusting as compared with the control
guinea pigs. By the eleventh day, normal appear-
ing hair had started to regrow at the sites of
inoculation, and the animals appeared clinically
cured by day 16.
In 7 animals, fed 15 mg/kg/day, a definite de-
crease in erythema was noted by the fourth day
after the start of treatment. However, no further
clinical improvement occurred until the eleventh
FIG. 4. GP 152. Infected with M. coals 13 days
previously.
day, when a decrease in sealing was noted. By
the sixteenth day, hair had started to regrow. The
animals appeared almost normal after 3 weeks,
while the infected sites in untreated animals at
this time remained slightly inflammatory.
In four animals fed 10 mg/kg/day, no clinical
improvement was noted during the first week
after start of therapy. On the ninth day there was
a slight but definite decrease in erythema, crust-
ing and edema. However, despite continued
treatment, no further improvement was noted dur-
ing the subsequent observation period which
could not he attributed to the spontaneous cure
process which normally occurs in untreated
infected guinea pigs.
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FIG. 1. GP 149. Infected with M. coals 13 days
prevlously. On day treatment with griseofulvin
started.
FIG. 3. GP 149. Two weeks after start of feed-
ings. Infected 27 days previously.
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In ten animals fed 6 mg/kg and in six animals
fed 3 mg/kg, the course of the fungous infection
appeared unaltered as compared with untreated
control animals.
In the course of these therapeutic assays, we
carried out comparative histologic studies of skin
biopsies from 16 guinea pigs infected with ill.
canis. Ten to twelve days after infection, 8 of the
FIG. 5. GP 152. Infected with M. canis 27 days
previously. No griseofulvin therapy. Compare
with Figure 3.
animals started to receive griseofulvin, 60 mg/kg,
5 times a week in the manner previously de-
scribed, and the rest were left untreated as con-
trols. Biopsy specimens were taken before the
start of therapy and on days 4 and 8 of therapy.
The sections were stained by the Hotehkiss-
McManus method and were read by Dr. Morris
Rothstein. * Typical sections are presented in
Figs. 6—8.
RESULTS
Before treatment, the sections showed numer-
ous hyphae in the horny layer and numerous in-
fected hairs and follicle walls in the epidermis;
40—85% of the hairs in the upper eutis were
involved. After four days of treatment, numerous
filaments were still present in the horny layer.
The hairs in the epidermis were infected while
the follicle walls were free of fungi. In the upper
cutis, only 10% of the hairs were infected. By the
eighth day, the number of fungous elements in
the horny layer was very much reduced and no
fungi could be seen in the hairs or follicle walls of
the epidermis or upper cutis. The untreated con-
*We wish to thank Dr. Morris Rothstein for his
help in evaluating the tissue sections.
FIG. 6. GP 69. Before start of griseofulvin therapy. Infected 10 days previously. Hotchkiss-Mc-
Manus stain.
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TABLE 1
Clinically apparent infection in guinea pigs
simultaneously infected with M. canis
and treated with griseofulvin
trol animals biopsied at the same intervals as
those receiving griseofulvin showed the full blown
features of fungous infection during the entire
period of observation.
EXPERIMENTS IN PROPHYLAXIS
In further tests, we attempted to ascertain the
minimum dose of orally administered griseofulvin
which will prevent the development of experi-
mental infection with M. canis. Guinea pigs were
exposed to M. canis by placing Woods light
positive hairs on slightly abraded areas on their
flanks. Starting on the day of infection, groups
of animals were fed varying amounts of griseo-
fulvin according to the schedule given in Table 1.
They were examined at weekly intervals for
clinical evidence of infection for three weeks.
RESULTS
The results of this experiment are presented in
Table 1. When a total of 50 mg per kg or more
of griseofulvin was fed per week, clinically
apparent disease was prevented during the three
week period of observation. Lower doses either
were essentially without effect, or, at best, de-
layed the appearance of clinical changes. How-
ever, it was noted that even in those animals
receiving as little as 10 mg/kg/week the lesions
which did develop were much smaller than in the
control animals.
EXPERIMENT ON DURATION OF PROPHYLACTIC
EFFECT FROM PRIOR MEDICATION
In another series of guinea pigs, we attempted
to ascertain whether the previous administration
of griseofulvin has a prophylactic effect on subse-
quent experimental infection with M. canis.
Groups of guinea pigs were fed varying
amounts of griseofulvin for varying lengths of
time. Three and six days after the last day of
treatment, the animals were challenged with M.
can.is and were then observed for 7—10 days for
signs of fungous infection.
RESULTS
The dosage schedules, time intervals and
results are presented in Table 2. This shows that
prefeeding griseofulvin for as long as three weeks,
at a level of 60 mg/kg, did not prevent the sub-
sequent development of fungous disease in
animals which were deliberately infected with M.
canis three days after discontinuation of treat-
ment.
DISCUSSION
ill. canis infections in guinea pigs responded
favorably to griseofulvin therapy as long as the
dose, given daily for five days during each week,
was at a level of 15 mg/kg/day or more. There
was some indication that with the higher doses,
cure took place at a significantly faster rate than
with the minimum effective dose of 15 mg/kg/
day. A dose of 10 mg/kg/day had a very slight
inhibitory but non-curative effect on M. canis
infection, while doses of 6 and 3 mg/kg/day had
no noticeable effects on established infections.
These findings appear to be in satisfactory agree-
No. of Animals
Infected After:
1 week 2 weeks 3 weeks
Griseoful-
yin per
Feeding,
mg/kg
60
30
15
10
15
15
10
5
10
2
2
No. of
Feedings
Per Week
5
5
S
5
3
2
3
5
2
5
3
Total
Weekly
Dose,
mg/kg
300
150
75
50
45
30
30
25
20
10
6
0
0/3
0/3
0/5
0/5
0/4
1/4
0/4
0/5
3/3
2/7
3/4
13/13
0/3
0/3
0/5
0/5
2/3
4/4
3/4
3/5
5/7
4/4
0/3
0/3
0/5
0/5
3/3
4/4
3/5
5/7
TABLE 2
Effects of preceding treatment with griseofulvin on
subsequent infection with M. canis
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ment with those of Gentles (cited in 2) and of
Swartz, et al. (8), who studied T. mentagrophytes
infections in guinea pigs.
If the results of our investigations in guinea
pigs are applicable to man, the presently used
average dose of 1000 mg per day represents the
minimum effective dose for a person weighing 70
kg. It would appear that a correspondingly higher
dose shou]d be administered in patients weighing
more than 70 kg. Furthermore, in patients where,
for one reason or another, healing within the
shortest possible time appears desirable, doses of
30 to 60 mg/kg/day would be indicated, unless
further experience in man suggests prohibitive
side effects at the higher dosage levels.
Although the minimal effective dose in man
has not yet been ascertained, our clinical experi-
ence to date is in accord with our results in
animals. In a few cases in children who received
such a small dose as 10 mg/kg/day for Ill.
audouini infections of the scalp, no beneficial
effects were observed.
We wish to call attention to still another find-
ing of ours which may be of clinical importance:
In guinea pigs treated with doses as high as 60
mg/kg/day, the previously infected but clinically
"cured" sites remained culturally positive at 14
days and longer. In fact, cultures from these
griseofulvin-fed animals did not start to become
negative until the cultures in untreated, control
animals began to become negative. We have noted
parallel findings in some of our patients, where
positive cultures still could be obtained from
previously infected sites, even though these
clinically appeared "cured." Indeed, some of
these patients subsequently developed clinical
recurrences of their disease after discontinuing
therapy. It must therefore be anticipated, since
griseofulvin is only a fungastatic (2), that, at
least in some cases it perhaps makes healthy
carriers out of patients who have been "cured"
of their active disease, i.e., possibly it does not
entirely eliminate all fungi from the skin even
after prolonged therapy. Such an effect would
not be unlike that seen in patients with furuncles
who have been treated systemically with broad
spectrum antibiotics; the medicament may help
to cure the furunculosis but certainly does not
eliminate all pathogenic staphylococci from the
patient's skin and does not prevent recurrences
once it has been discontinued.
Our histologic studies tend to support the
possibility that pathogenic fungi may survive in
the patient's skin for some time after clinical
"cure". During griseofulvin therapy fungi rapidly
disappear from the hairs and hair follicles of
guinea pigs, but not as rapidly from their surface
horny layers. Sections obtained after 4 daily
feedings of 60 mg/kg showed a decrease in the
number of infected hairs and follicles in the upper
cutis, no fungi in the lower cutis, but no marked
reduction in the number of fungi in the horny
layer. This is during the phase when reduction of
erythema was first noted. After eight days, when
the animals were in the process of "cure", sections
showed no fungi in hairs or follicle walls but the
horny layer still showed some fungi, although in
markedly reduced numbers.
Our attempts to prevent infections showed
that, if treatment is started simultaneously with
exposure to M. canis, active disease can b'
prevented with 50 mg/kg/week. This amount is
equivalent to 9 the minimal therapeutic dose in
guinea pigs. It appears, therefore, that perhaps
once active disease has been "cured", it may be
possible to prevent recurrences by maintaining
patients on 10 mg/kg/day. However, our find-
ings in guinea pigs clearly demonstrate that as
early as three days after discontinuation of
griseofulvin therapy in doses as high as 60 mg/
kg/day, the skin is unprotected against infection
with M. canis. Similar findings have been seen in
the independent studies of Swartz, et at (8).
SUMMARY
1. Guinea pigs infected with M. canis re-
sponded favorably to force feedings of griseofulvin
at a level of 15 mg or more per kg five times a
week as evidenced by accelerated clinical healing
of the lesions as compared with controls. Cul-
tures, however, still were positive at that time.
Biopsy studies showed rapid disappearance of
fungi from infected hairs and hair follicles, but
reduced numbers of fungi were still demonstrable
in the horny layer eight days after inception of
treatment. The possible implications of these
findings regarding therapeutically effective doses
in man and regarding recurrences of "cured"
infections are discussed.
2. When griseofulvin therapy was started
simultaneously with deliberate infection with M.
canis, a dose of 50 mg/kg/week was found to be
the minimal dose required to prevent infection.
Thus, in guinea pigs, the minimal preventive dose
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is the minimal curative dose. The possible im-
plications of these findings regarding prevention
of recurrences in "resistant" fungous infections
in man are discussed.
3. It was found that the protective effect of
griseofulvin is lost within 3 days after the drug
has been discontinued.
Editor's note: This paper was discussed jointly
with that of Frank J. Roth, Jr., Bennett Saliman
and Harvey Blank, "In Vitro Studies of the
Antifungal Antibiotic Griseofulvin" which im-
mediately precedes the present paper.
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DISCUSSION
DR. JACOB H. SWARTZ (Boston, Mass.): I
should like to ask Dr. Roth if tests for hemolysis
were done with griseofulvin? I should also like to
ask whether mutants developed following treat-
ment with griseofulvin? If so, were these mutants
more resistant to this antifungal antibiotic?
DR. BERNARD GORDON (Bellevue Hospital,
New York City): On behalf of Dr. Fred Reiss I
would like to comment on the clinical and
mycological effects of griseofulvin as seen on
treating 30 children (ages 2 to 11) with ringworm
infections of the scalp at Bellevue hospital.
Griseofulvin (250 mg. twice a day) was ad-
ministered orally to 25 children with M. audouini
infections of the scalp. The average length of time
to cure ranged from 21 to 74 days. The average
was 44 days.
Our criterion for cure was two consecutive
negative cultures.
Five children with T. ton.surans infections of
the scalp were cured in an average of 53 days.
The range was from 36 to 75 days.
There were no side effects.
During therapy the morphological character-
istics of M. audouini in the hair revealed transi-
tion from the typical microid mosaic pattern of
the spores to frequent formation of hyphal
elements. After the 3rd week of therapy, these
hyphae showed rectangular fragmentation and
groups of bizarrely shaped spores.
In T. tonsurans infections during therapy one
sees transformation of the round endospores into
rectangular anthrospores and eventually irregu-
larly shaped, bizarrely outlined, distorted hyphae.
DR. PAUL H. JACOBS (Washington, D. C.): I
enjoyed both papers and the beautiful pictures.
I would like to ask two questions: 1, regarding
the time lag period after the pellets were removed
from the griseofulvin solution, did this vary in
length depending upon how long they were in
the solutions; and 2, was any resistance noted
in the organisms studied?
DR. LOUIS H. WINER (Beverly Hills, Calif.):
I had the pleasure of reading and discussing a
paper by Dr. Harry Robinson et at. on Grifulvin*.
Using cultures of Trichophyton rvbrum and
Micros poron canis and transpiating the organisms
to gradually increased strengths of Grifulvin in
vitro. Has anyone been able to obtain positive
animal inoculation with this type of attenuated
organism.
DR. LAWRENCE C. GOLDBERG (Cincinnati,
Ohio): We heard what the minimum amount of
griseofulvin was necessary to cure the fungus
infection in these animals. By any chance does
anyone know how much griseofulvin would have
to be given to kill a guinea pig.
*Griseofulvin of McNeil.
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DR. A. J. ORFUSS (New York, N. Y.): I would
like to know, firstly whether there were any
reactions in the animals that were given this
antibiotic, and secondly, how does Dr. Rosenthal
know the dose that these animals received pre-
cisely? Was this material given in the water these
animals were drinking, and if so, what was the
way he determined the amount that they
received?
DR. FRANK J. ROTH (in closing): In answer to
the first question, we have not undertaken any
direct studies on the possible hemolytic activity
of griseofulvin. No such action has been ob-
served, however, in any of our clinical trials of
the antibiotic. A number of other investigators
have evaluated the drug in this respect and have
found no indication of such an effect.
We have not as yet observed any hereditary
changes in the morphology or metabolism of
sensitive fungi following their exposure to gris-
eofulvin. Culture isolates obtained from patients
on therapy and dermatophytes introduced and
maintained in varying concentrations of the
antibiotic have been carefully studied. A pro-
longed lag phase is observed after a dermato-
phyte has been removed from an inhibitory con-
centration of the antibiotic. This lag period is
especially evident after the fungus has resided
for 10 days or more in a minimal inhibitory con-
centration of griseofulvin. We believe that there
is a loose binding of the antibiotic to the my-
celium or a small intracellular depot formed which
must be dissociated or removed by elution before
a normal rate of growth can be resumed. With
higher concentrations a state of enforced dor-
mancy is produced in susceptible fungi—a state
which must first be broken before growth will
occur. Efforts to establish a persistent retardation
of growth by prior treatment of the fungus with
griseofulvin have been unsuccessful. Strains of
Trichophyton rubrum which showed an increase
of the minimal inhibitory concentration to 1.8
mgm./ml. developed normally in media free of
the antibiotic and upon reassay demonstrated
.a drop back to the original sensitivity (0.20
mgm. /ml.). This observation was considered to
represent transitory adaptation or "training"
phenomenon on the part of the fungus.
I am familiar with Dr. Robinson's recent work
on the induction of resistance to griseofulvin by
dermatophytes. Our studies in this area, as re-
ported in our manuscript, have been restricted to
one species, Trichophyton rubrum. We have been
unable to demonstrate significant adaptation or
produce resistant mutants even after prolonged
exposure of the fungus to the antibiotic. The work
of Dr. Robinson on induced resistance was done
with other species of dermatophytes.
I believe the remaining questions can best be
answered by Dr. Rosenthal.
Da. S. A. ROSENTHAL (in closing): The findings
in our laboratory concerning increased resistance
of Trichophyton rubrum and other pathogenic
fungi to griseofulvin are in agreement with Dr.
Roth. We have been able to grow T. rubrurn on
increasingly higher concentrations of griseofulvin
by culturing the parent strain on subinhibitory
concentrations of this drug. Using a technic
different from that of Dr. Roth, certain of our
strains of T. rubrum were made to grow in con-
centrations as high as 7 micrograms per milliliter.
However, these so-called resistant strains, when
transferred back onto ordinary Sabouraud's
medium for one generation, lost all increased
resistance and became just as susceptible as the
parent cultures.
Dr. Robinson has apparently anticipated us.
We have experiments in progress now attempting
to induce resistance to griseofulvin in Micro-
.sporum canis. If we develop resistance in this
fungus, we plan to inoculate the resistant strain
into guinea pigs, treat them with griseofulvin and
compare them with treated animals infected with
a non-resistant strain.
I cannot tell you the maximum amount that
can be fed to guinea pigs. We have fed some of
our animals up to five weeks at a level of 60 mg.
per kilogram five days a week with no apparent
adverse effect. Perhaps Dr. Hildick-Smith may
have more information on that. As much as 200
mg. per kg. given intravenously in rats does not
kill, although it causes inhibition of mitotic
activity (Paget, G. E. and Walpole, A. L.: Some
cytological effects of griseofulvin. Nature, 182:
1320—1321, 1958).
I think I have answered Dr. Orfuss' questions,
except that the amount of griseofulvin to be fed
was determined by weighing the animals and
force-feeding the calculated amount of a 30 mg/
ml water suspension of griseofulvin.
